Enlarge / We’ve all been there. (credit: Getty | Ute Grabowsky) A fast-acting drug that shortens influenza infections with a single dose has earned a priority review from the US Food and Drug Administration and—if approved—has the chance of hitting the market in 2019 amid the upcoming flu season. That’s all according to Genentech, the […]
